TNFα inhibitors as targets for protective therapies in MSA: a viewpoint

Abstract Multiple system atrophy (MSA) is a unique and fatal α-synucleinopathy associated with oligodendroglial inclusions and secondary neurodegeneration affecting striatum, substantia nigra, pons, and cerebellum. The pathogenesis remains elusive; however, there is emerging evidence suggesting a pr...

Full description

Bibliographic Details
Main Authors:	Alain Ndayisaba, Kurt Jellinger, Thomas Berger, Gregor K. Wenning
Format:	Article
Language:	English
Published:	BMC 2019-04-01
Series:	Journal of Neuroinflammation
Subjects:	TNFα TNFα inhibitors Multiple system atrophy Neuroinflammation Neurodegeneration Disease-modifying treatment
Online Access:	http://link.springer.com/article/10.1186/s12974-019-1477-5

id	doaj-654dff1b050748dda4fae3d106b69537
record_format	Article
spelling	doaj-654dff1b050748dda4fae3d106b695372020-11-25T02:58:38ZengBMCJournal of Neuroinflammation1742-20942019-04-011611710.1186/s12974-019-1477-5TNFα inhibitors as targets for protective therapies in MSA: a viewpointAlain Ndayisaba0Kurt Jellinger1Thomas Berger2Gregor K. Wenning3Division of Clinical Neurobiology, Department of Neurology, Medical University of InnsbruckInstitute of Clinical NeurobiologyDepartment of Neurology, Medical University of ViennaDivision of Clinical Neurobiology, Department of Neurology, Medical University of InnsbruckAbstract Multiple system atrophy (MSA) is a unique and fatal α-synucleinopathy associated with oligodendroglial inclusions and secondary neurodegeneration affecting striatum, substantia nigra, pons, and cerebellum. The pathogenesis remains elusive; however, there is emerging evidence suggesting a prominent role of neuroinflammation. Here, we critically review the relationship between αS and microglial activation depending on its aggregation state and its role in neuroinflammation to explore the potential of TNFα inhibitors as a treatment strategy for MSA and other neurodegenerative diseases.http://link.springer.com/article/10.1186/s12974-019-1477-5TNFαTNFα inhibitorsMultiple system atrophyNeuroinflammationNeurodegenerationDisease-modifying treatment
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Alain Ndayisaba Kurt Jellinger Thomas Berger Gregor K. Wenning
spellingShingle	Alain Ndayisaba Kurt Jellinger Thomas Berger Gregor K. Wenning TNFα inhibitors as targets for protective therapies in MSA: a viewpoint Journal of Neuroinflammation TNFα TNFα inhibitors Multiple system atrophy Neuroinflammation Neurodegeneration Disease-modifying treatment
author_facet	Alain Ndayisaba Kurt Jellinger Thomas Berger Gregor K. Wenning
author_sort	Alain Ndayisaba
title	TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title_short	TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title_full	TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title_fullStr	TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title_full_unstemmed	TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title_sort	tnfα inhibitors as targets for protective therapies in msa: a viewpoint
publisher	BMC
series	Journal of Neuroinflammation
issn	1742-2094
publishDate	2019-04-01
description	Abstract Multiple system atrophy (MSA) is a unique and fatal α-synucleinopathy associated with oligodendroglial inclusions and secondary neurodegeneration affecting striatum, substantia nigra, pons, and cerebellum. The pathogenesis remains elusive; however, there is emerging evidence suggesting a prominent role of neuroinflammation. Here, we critically review the relationship between αS and microglial activation depending on its aggregation state and its role in neuroinflammation to explore the potential of TNFα inhibitors as a treatment strategy for MSA and other neurodegenerative diseases.
topic	TNFα TNFα inhibitors Multiple system atrophy Neuroinflammation Neurodegeneration Disease-modifying treatment
url	http://link.springer.com/article/10.1186/s12974-019-1477-5
work_keys_str_mv	AT alainndayisaba tnfainhibitorsastargetsforprotectivetherapiesinmsaaviewpoint AT kurtjellinger tnfainhibitorsastargetsforprotectivetherapiesinmsaaviewpoint AT thomasberger tnfainhibitorsastargetsforprotectivetherapiesinmsaaviewpoint AT gregorkwenning tnfainhibitorsastargetsforprotectivetherapiesinmsaaviewpoint
_version_	1724705871458467840

TNFα inhibitors as targets for protective therapies in MSA: a viewpoint

Similar Items